摘要
Abstract
Objective:To investigate the clinical efficacy of Paclitaxel combined with Epirubicin neoadjuvant chemotherapy in the treatment of triple-negative breast cancer.Method:Our hospital from February 2012 to October 2013 were treated 50 cases of triple-negative breast cancer patients for the study, they were divided into the control group(n=25) and the treatment group(n=25),the control group was given the pure Epirubicin adjuvant chemotherapy,the treatment group was given Paclitaxel combined with Epirubicin neoadjuvant chemotherapy,the treatment effect and adverse reactions of two groups were compared.Result:The treatment group,complete remission in 8 cases(32%),partial remission in 12 case(48%),the recent total effective rate was 80%.The control group,complete remission in 4 cases(16%),partial remission in 10 case(40%),the recent total effective rate was 56%,the difference was statistically significant(P<0.05).Conclusion:Paclitaxel combined with Epirubicin neoadjuvant chemotherapy in the treatment of triple-negative breast cancer has a good efficacy,is worthy of further research applications.关键词
紫杉醇/表柔比星/新辅助化疗方案/三阴性乳腺癌Key words
Paclitaxel/Epirubicin/Neoadjuvant chemotherapy/Triple-negative breast cancer分类
医药卫生
